Lymphoma is reported the most common tumor of hematological malignancy cancer or blood cancer, in the developed countries. There are two major types of lymphoma that are Hodgkin's lymphoma and non-Hodgkin's lymphoma. Approximately 85% of non-Hodgkin's lymphomas from B cells, an essential part of the individual immunity. B-cell lymphoma usually arises in the lymph nodes or lymphoid tissues, including the blood, spleen, bone marrow, and so on. In order to establish a murine model for the monoclonal anti-idiotype therapy of B cell lymphomas, a group of different rat monoclonal anti-idiotype antibodies are generated against the surface immunoglobulin (Ig) of the murine B cell tumor 38C13. And xenogeneic antibodies are made of the fusion of rat spleen cell immunized with the 38C13 idiotype. CD44, also known as CD44 antigen, ECMRIII (Extracellular matrix receptor III), HCAM (Homing cell adhesion molecule), Pgp-1 (phagocytic glycoprotein-1), HUTCH-1, etc., is cell surface adhesion receptor and transmembrane glycoprotein in humans encoded by the CD44 gene on the chromosome 11p13. It is a ubiquitous glycoprotein produced throughout the body with a molecular weight of about 85-200 kDa. CD44 contains certein primary domains inclduing the ectodomain, the transmembrane and intracellular domain. It is probably the most well-characterized receptor for hyaluronic acid (HA) and has been reported to be involved in adhesive cell-cell and cell-matrix interactions, cell migration and cell homing. CD44 is also a widely distributed transmembrane adhesion molecule with high expression in cancers.